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Abstract
Introduction: The purpose of this research is to assess the effects of oral ibandronate on bone microarchitecture
by using high-resolution peripheral quantitative computed tomography (HR-pQCT) in patients with systemic lupus
erythematosus (SLE) taking a long-term glucocorticoid.
Methods: In this double-blind placebo-controlled study, 40 Chinese female SLE patients taking prednisolone were
randomly assigned to receive either monthly oral ibandronate (150 mg) or placebo with daily 1-
hydroxycholecalciferol (Alfacalcidol; 1 μg) and calcium supplement for 12 months. Assessments of bone
microarchitecture by using HR-pQCT and area bone mineral density (aBMD) of the lumbar spine and hip with dual-
energy x-ray absorptiometry (DXA) were performed at baseline and 12 months.
Results: No differences in baseline characteristics were found between the two groups. After 12 months, no
statistical differences were noted in any of the bone densities, microarchitectural parameters, or percentage
changes of these parameters, as measured with HR-pQCT or DXA between the two groups. However, within the
active group, the percentage improvement was significant in cortical bone density (P = 0.023) which was absent in
the placebo group. Improvement was also seen in the aBMD of both the lumbar spine (P < 0.0001) and the hip
(P < 0.005). In the placebo group, the percentage increase in trabecular separation was significant (P = 0.04), and
the percentage improvement in aBMD in the spine also was significant (P = 0.049).
Conclusions: Oral ibandronate treatment improves microarchitecture in SLE patients taking long-term
glucocorticoid assessed with HR-pQCT, and this new technology may have a role in assessing bony changes in
future longitudinal studies in SLE patients.
Trial registration: ClinicalTrials.gov identifier: NCT00668330.
Introduction
Patients taking a glucocorticoid who have sustained ver-
tebral and nonvertebral fractures have an increase in
mortality rate and a higher risk of subsequent fractures
[1-4], with a reduction in quality of life [5] during the
subsequent decade [6]. In some patients, the increase in
risk is evident within 3 months of starting glucocorti-
coids [7,8]. Patients receiving long-term glucocorticoids,
such as patients with systemic lupus erythematosus
(SLE), are similarly at risk of developing osteoporosis
and fractures. We and others have demonstrated that
patients with SLE have a high prevalence of asympto-
matic vertebral fractures, even with normal area bone
mineral density (aBMD) [9-11]. This suggests two pro-
blems: an inherent limitation of measurement of aBMD
with dual-energy x-ray absorptiometry (DXA) for clini-
cal assessment of bone-fracture risk, and that glucocorti-
coids lead to deterioration of bone quality, which cannot
be measured with the DXA measurements. Independent
of glucocorticoids, other factors in SLE may affect bone
quality, including immobilization; vitamin D deficiency;
hypogonadism, the presence of inflammatory cytokines;
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medium, provided the original work is properly cited.renal failure; and medications, including glucocorticoids,
methotrexate, anticoagulants, and anticonvulsants [9].
We recently showed, by using high-resolution peripheral
quantitative computed tomography (HR-pQCT), altera-
tions of bone density and microarchitectures in SLE
patients with vertebral fractures when the DXA was
unable to show any differences between those with and
without vertebral fractures [12]. Two cross-sectional stu-
dies reported that bone microarchitecture, measured by
HR-pQCT at the distal radius, can distinguish postme-
nopausal women with and without fragility fractures,
partly independent of aBMD [13,14]. For these reasons,
we investigated the effectiveness of using HR-pQCT to
determine the effects of a bisphosphonate that has been
established in the treatment of glucocorticoid-induced
osteoporosis [15-22]. Thus, this is the first study using
this new technique to assess treatment-related changes
in bone architecture in patients with glucocorticoid-
induced osteoporosis.
Intravenous ibandronate is a potent nitrogen-containing
bisphosphonate with established therapeutic efficacy and
tolerability for patients with established glucocorticoid-
induced osteoporosis [23,24]. Other bisphosphonates with
similar effects are risedronate, alendronate, and zoledronic
acid [15-19,21,22,25-27]. The oral preparation of ibandro-
nate, however, has not been shown to be effective in glu-
cocorticoid-induced osteoporosis, although it is efficacious
in preventing bone loss in postmenopausal women
[28,29], with a significant reduction in vertebral fracture
risks [30-32]. Ibandronate shares a similar molecular
mechanism with alendronate and risedronate [33]; thus it
should also be useful in the prevention and treatment of
glucocorticoid-induced osteoporosis. The aim of the study
is to evaluate its effects in patients with SLE receiving glu-
cocorticoids, by using HR-pQCT and DXA.
Materials and methods
Study design
In the 12-month randomized controlled trial, 40 Chinese
female patients with a diagnosis of SLE, according to the
American College of Rheumatology revised criteria for
the classification of SLE [34], were recruited. All partici-
pants had been taking glucocorticoids uninterrupted for
at least 1 year at a daily dose of at least 2.5 mg predniso-
lone and with a T score of 0.4 SD or less at the lumbar
spine (L1 to L4) or hip, measured with DXA. Exclusion
criteria were creatinine clearances of less than 30 ml/
min; a history of renal stones; hypocalcemia; primary
hyperparathyroidism; hyperthyroidism; hypothyroidism;
metabolic bone diseases; a history of recent serious gas-
trointestinal tract disease, such as esophagitis; and cur-
rently taking bone-active drugs, such as hormone-
replacement therapy, anabolic steroids, calcitonin, active
vitamin D3 analogues, fluorides, anticonvulsants, or
bisphosphonates. Patients who were pregnant or breast-
feeding also were excluded. The study was approved by
the ethics committee at The Chinese University of Hong
Kong. All participants provided written informed
consent.
The patients were randomly assigned to receive oral
treatment with either daily 1-hydroxycholecalciferol
(Alfacalcidol; 1 μg) and a monthly placebo tablet of
ibandronate (placebo group, 20 patients) or monthly
oral ibandronate (150 mg) and daily Alfacalcidol (1 μg)
(active group, 20 patients). All participants received one
calcium tablet per day that contained 500 mg of elemen-
tal calcium. Study drugs were given at baseline and fol-
low-up visits. Patients were well instructed about how
to take the study drugs, and related precautions were
given. Clinical assessments were performed at baseline
and every 3 months. Side effects related to the drug
were recorded during each follow-up visit.
The primary outcome was the percentage change in
density and architecture of cortical and trabecular com-
ponents, as measured with HR-pQCT from baseline to
12 months.
The secondary outcome was the percentage change in
aBMD of the lumbar spine and hip from the baseline at
12 months.
Assessment of SLE
Demographic variables included age, body height, body
weight, and menopausal status. Clinical assessment of
SLE included disease duration since diagnosis, disease
activity, damage, and laboratory assessment. Disease
activity and damage were assessed by using the SLE Dis-
ease Activity Index (SLEDAI) and the Systemic Lupus
International Collaborating Clinics/American College of
Rheumatology Damage Index (SDI), respectively. A
higher score on these two indices indicates higher dis-
ease activity and disease damage. Ever having had lupus
nephritis, as defined as 24-hour proteinuria more than 0.5
g, was recorded by reviewing medical notes. Laboratory
assessments included titers of anti-double stranded DNA
(ds-DNA), complement level (C3 and C4), C-reactive
protein (CRP), and creatinine clearance. Use of glucocorti-
coids, including duration, current dose, highest dose ever,
and cumulative dose, also was recorded through chart
review.
Measurements of aBMD
aBMD measurements of the hip and the lumbar spine
(L1 to 4; anteroposterior view) were performed by a
trained technician with the same DXA equipment
(model 4500A; Hologic, Bedford, MA) in all patients at
baseline and at 12 months. Results were expressed in
grams per square centimeter. The aBMD values of both
lumbar spine and hip were compared with the aBMD
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[35].
Assessment of bone volumetric density and architecture
Microarchitecture of the bone was measured in the non-
dominant distal radius by using a 3 D HR-pQCT device
(XtremeCT; Scanco Medical AG, Bruttisellen, Switzer-
land), at baseline, 6 months, and 12 months. This
system uses a two-dimensional detector array in combi-
nation with an 0.08-mm point-focus x-ray tube, enabling
the simultaneous acquisition of a stack of parallel CT
slices with a nominal isotropic resolution (voxel size) of
82 μm. The details of image acquisition and analysis
have been described previously [13]. At the distal radius,
110 CT acquisitions were obtained, providing 3 D volu-
metric representation of a total thickness of approxi-
mately 9 mm. The entire volume of interest was
automatically separated into cortical and trabecular
components, yielding average bone density (D100), tra-
becular bone density (Dtrab), meta-trabecular bone den-
sity (Dmeta), inner-trabecular bone density (Dinn), and
cortical bone density (Dcomp) in milligrams HA/cc.
Mean cortical thickness (Ct.Th) was defined as the
mean cortical volume divided by the outer bone surface.
Trabecular bone volume fraction (BV/TV) was derived
from trabecular density, assuming fully mineralized
b o n et oh a v ead e n s i t yo f1 . 2gH A / c c .B yu s i n g3D
HR-pQCT datasets, metric indices of topologic features
of trabecular bone structure could be directly assessed
by measuring distances in 3 D space [36]. Trabecular
number (Tb.N.) was taken as the inverse of the mean
distance between the midaxes of the observed trabecular
structure. The midaxes of the trabecular structure were
assessed from the binary 3 D image dataset by using the
3 D distance transformation and extracting center points
of nonredundant spheres that filled the structure com-
pletely. Combining Tb.N and BV/TV led to trabecular
thickness (Tb.Th) = BV/TV/Tb.N, and trabecular
separation (Tb.Sp) = (1-BV/TV)/Tb.N in analogy to
standard histomorphometry. A standard deviation of 1/
Tb.N (Tb.1/N.SD) was used to reflect trabecular net-
work inhomogeneity. The in vivo precision error of den-
sity (total, trabecular and cortical) measurement,
expressed as the coefficient of variation, ranged from
0.7% to 1.5%.
Randomization
The method of concealed random allocation was used.
Simple randomization was conducted with a computer-
generated random list from School of Pharmacy, the
C h i n e s eU n i v e r s i t yo fH o n gK o n g .T h ep r o j e c tc o o r d i -
nator and other investigators were blind to the randomi-
zation and the group assignments. The code was broken
at the end of the clinical trial.
Statistical analysis
Statistical analysis was performed by using The Statistics
Package for Social Sciences (SPSS for Windows, version
13.0, 2006; SPSS Inc, Chicago, IL). Descriptive statistics
were used to summarize baseline, 12-month, and base-
line to 12-month changes in all measures. Results were
expressed as median and IQR. Continuous variables
were compared with the Mann-Whitney U test (with
nonnormal distribution). Paired-samples t tests were
used to compare baseline measures with 12-month mea-
sures. Categoric variables were compared with the c
2
test. Robustness of the results was examined by using
both raw and percentage change of the measures in the
analyses.
Results
In total, 40 women with a mean (SD) age of 44 (8.7)
years were enrolled. All subjects completed the 12-
month study period. Twelve patients had active nephri-
tis at baseline, six from each group. Four patients flared
at 12 months, as defined by a change in SLEDAI > 6,
three from the placebo group, and one from the active
group. No significant changes in SLEDAI were found at
the end of the study. No adverse side effects were attrib-
uted to the study drug reported in either group of
patients during the study period.
No patients in either group had experienced previous
vertebral fractures. The two groups were comparable in
terms of baseline demographics and clinical characteris-
tics (Table 1). All participants had received prednisolone
before treatment for a median duration of 12.7 years in
the placebo group and 13.4 years in the active group
(no significant difference). No smokers were reported.
Approximately more than half of the subjects were post-
menopausal. A majority of patients had a history of
lupus nephritis, and the disease activity was mild at the
time of entry into the study. The median (IQR) daily
current doses of glucocorticoid were 5 (5, 7.5) mg in
both groups at baseline. The median total cumulative
dose of glucocorticoid in both groups was similar, with
33,177.7 mg for the placebo group and 32,329.3 mg for
the active group. Approximately 50% of the patients in
both treatment groups were taking at least one other
concomitant medication at baseline, in addition to pre-
dnisolone. All participants were receiving calcium
supplementation.
The aBMD, T scores of lumbar spine/hip, percentage
of osteoporosis/osteopenia, as well as volumetric density
and architecture assessed by HR-pQCT did not differ
between the two groups at baseline (Table 2).
Primary outcome
After 12 months, between the two groups, no statistical
differences were found in any o ft h ev o l u m e t r i cd e n s i t y
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the parameters between baseline and 12 months, mea-
sured with the HR-pQCT (Table 2).
Within the active group, significant improvement in
cortical bone density (Dcomp) was noted (P =0 . 0 2 3 ) ,
which was absent in the placebo group. The median
percentage improvement in cortical bone density
(Dcomp) in the active group was 0.6, as opposed to 0.45
in the placebo group (not significant). A trend toward
improvement in trabecular bone density (Dtrab) and tra-
b e c u l a rb o n ev o l u m et ot i s s u ev o l u m e( t B V / T V )w a s
seen, which was absent in the placebo group.
In contrary, in the placebo group, a significant dete-
rioration of trabecular separation (Tb.Sp) was observed
(P = 0.04). The median percentage deterioration in tra-
becular separation (Tb.Sp) was 3.9 compared with 0.05
in the active group (not significant). A trend toward
worsening in trabecular number (Tb.N.) was found (P =
0.06) in the placebo group but not in the active group.
Secondary outcome
After 12 months, between the two groups, no statistical
significance was noted in the measures of aBMD of the
lumbar spine and hip. In the placebo group, statistical
improvement in aBMD occurred in the lumbar spine
(P = 0.049) but not in the femoral hip at 12 months. In
the active group, improvements were noted in the BMD
of both the lumbar spine (P < 0.0001) and the femoral
hip at 12 months (P < 0.005). However, the median per-
centage improvement in the aBMD of the lumbar spine
between the placebo and the active group was statisti-
cally significant: 2.6% versus 4.9% (P = 0.024), whereas
the median percentage change in the aBMD of the hip
between the two groups was not significant (0.83% in
the placebo group versus 1.0% in the active group).
Discussion
In this study, increases of 4.9% and 1% were found in
the aBMD in the active group in both lumbar spine and
femoral hip, respectively, after treatment with ibandro-
nate, despite not observing significant changes at these
sites between the two groups. The findings are consis-
tent with the findings of previous studies that examined
the efficacy of bisphosphonates in glucocorticoid-
induced osteoporosis [15-19,21,22,25-27], including one
in which the intravenous preparation of ibandronate was
used [24]. The small sample size and the relatively short
duration of treatment in the study may account for the
lack of differences seen between the groups. In the pla-
cebo group, the significant improvements in the aBMD
of the spine can be attributed to the known beneficial
effects of Alfacalcidol that counteract the detrimental
effects of glucocorticoid [37,38].
Most of the previous studies on glucocorticoids in SLE
have concentrated on the aBMD alone, even though it is
well established that prednisolone leads to deterioration
of bone quality that cannot be measured with the DXA
measurements. For these reasons, we used a novel tech-
n i q u eo fH R - p Q C Tt oa s s e s sb o n eq u a n t i t ya n dq u a l i t y
Table 1 Baseline demographic and clinical characteristics
of patients in placebo and active group
Placebo group
(n = 20)
Active group
(n = 20)
Demographic variables
Age, years 45.5 (0.5, 49) 47 (33.5, 50)
Height, cm 156.6 (151.5, 158.5) 157.0 (151.9, 160.4)
Weight, kg 50.3 (44.1, 63.5) 50.5 (46.6, 56.9)
Menopausal, number (%) 13 (65%) 11 (55%)
Duration of menopause,
years
2 (0-6.5) 0.5 (0-3)
Clinical variables
Disease duration, years 12.7 (8.8, 18.8) 13.4 (9.6, 18.8)
SLEDAI score 2.0 (0, 2.8) 2.0 (0, 3)
SDI score 1 (0.3, 1) 1 (0, 2)
Anti-ds DNA 31.5 (0-188) 0 (0-81)
C3, mg/L 0.92 (0.71, 1.12) 0.85 (0.65,0.97)
C4, mg/L 0.22 (0.16, 0.26) 0.18 (0.10, 0.23)
CRP, mg/L 1.1 (0.5-5.5) 0.5 (0.5-1.7)
Creatinine clearance, ml/
min
74 (46.9, 108.8) 73.0 (55.5, 86.5)
Ever had lupus nephritis,
number (%)
17 (85) 13 (65)
Use of glucocorticoids
Duration of
glucocorticoids, years
12.7 (8.5, 18.8) 13.4 (9.8, 20.1)
Current dose of
prednisolone, mg/day
5 (5, 7.5) 5 (5, 7.5)
Highest dose of
prednisolone, mg/day
40 (30, 40) 40 (30, 50)
Cumulative dose of
glucocorticoids, mg
33, 177.7 (22, 642.6,
44, 473.0)
32, 329.3 (20, 448.9,
43, 385.1)
T-score of DXA
Lumbar spine -1.45 (-1.78, -0.93) -1.10 (-1.65, -0.5)
Hip -1.15 (-1.58, -0.5) -1.15 (-1.75, -0.7)
Osteoporosis, number (%)
Lumbar spine 2(10) 2 (10)
Hip 0 (0) 1 (5)
Osteopenia, number (%)
Lumbar spine 13 (65) 11 (55)
Hip 12 (60) 11(55)
Data are expressed in median (IQR), unless specified otherwise. SLEDAI,
Systemic Lupus Erythematosus Disease Activity Index; SDI, Systemic Lupus
International Collaborating Clinics/American College of Rheumatology Damage
Index; anti-ds DNA, anti-double-stranded DNA; C3, C4, complement 3, 4; CRP,
C-reactive protein; DXA, dual energy x-ray absorptiometry; IQR, interquartile
range.
Creatinine clearance measurements were done only in those with active
nephritis, as defined as 24-urine protein > 0.5 g.
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studies have shown that glucocorticoid causes low bone
turnover [39], a loss of connectivity [40], and disrupted
bone geometry, with reduction of bone-formation rate
on the periosteal surface [41] that can lead to reduced
bone mineralization [42]. Some of these factors may
lead to bone fragility in patients with SLE. It is not sur-
prising that we and others have observed a much higher
incidence of asymptomatic vertebral fractures and non-
vertebral fractures in SLE cohorts [9-11], despite normal
aBMD values [1-4,43]. Similarly, the determination of
bone quality is of equal importance as bone quantity
when assessing the efficacies of new therapeutic agents.
HR-pQCT can achieve an isotropic voxel size of
about 80 μm at an acceptable radiation dose, yielding
high-resolution image data that allow good depiction of
trabecular and cortical bone. With this validated nonin-
vasive new technique, we previously detected significant
microarchitectural differences between patients with and
those without vertebral fracture [12].
Despite not observing any differences in architectural
parameters between the two groups, we demonstrated a
significant percentage increase in Dtrab, BV/TV, and
Dcomp after treatment with ibandronate in the active
group. In the placebo group, a significant decrease
occurred in Tb.N., with an increase in Tb.Sp.
Previous studies using other modalities of assessment
examined bone architecture in patients with glucocorti-
coid-induced or postmenopausal osteoporosis treated
with bisphosphonates. They focused on conventional
2-D histomorphometry from iliac crest bone-biopsy spe-
cimens [44], and some used 3-D microcomputed tomo-
graphy (μCT) [45-47]. Their overall results showed that
bisphosphonates were beneficial, with improvement in
trabecular microarchitecture, bone strength, and minera-
lization. A recent study using high-resolution MRI
demonstrated improvements in trabecular microstruc-
ture in patients receiving antiresorptive therapy [48].
Some limitations are present in our study. First, parti-
cipants were of high heterogeneity, regarding severity or
activity of disease, menopausal status, or treatment,
which decreased the generalizability of our results. Sec-
ond, the small sample size and the relatively short dura-
tion of treatment could account for the lack of
differences seen between the two groups. Third, we did
not measure the level of 25-hydroxyvitamin D, which is
an important bone parameter. Fourth, we analyzed the
minimal clinically important difference (MCID) by using
effect size for various measurements of HR-pQCT.
However, the effect sizes were all less than 0.2. Com-
pared with previous studies of bisphosphonates using
other devices such as micro-CT, the percentage changes
Table 2 Results of HR-pQCT variables in placebo and active group at baseline and at 12 months
Placebo group Active group
Variables Baseline 12 months Change (%) P value Baseline 12 months % change p value
aBMD spine,
g/cm
2
0.83 (0.80, 0.90) 0.84 (0.79,0.90) 2.6 (0.03, 4.3) 0.049 0.87 (0.81,0.93) 0.89 (0.86, 0.98) 4.9 (1.7, 5.9) < 0.001
aBMD hip,
g/cm
2
0.75 (0.71, 0.83) 0.74 (0.71, 0.84) 0.8 (-0.9, 2.7) NS 0.76 (0.70, 0.82) 0.76 (0.73, 0.84) 1.0 (0.3, 2.5) 0.005
D100,
mHA/cc
360.3 (314.2,373.8) 358.4 (313.1, 372.3) -0.1 (-1.1, 1.3) NS 332.0 (268.6, 375.1) 333.9 (269.9, 369.3) 0.5 (-0.6, 1.6) NS
Dcomp, mg
HA/cc
931.9 (860.2, 962.1) 936 (866.5, 962.3) 0.45 (-0.8, 1.2) NS 901.6 (846.2, 964.6) 910.2 (857.5, 967.3) 0.6 (0.03, 1.4) 0.023
Ct. Th, mg
HA/cc
0.89 (0.65, 0.96) 0.88 (0.66, 0.97) 0.0 (-1.5, 1.3) NS 0.80 (0.62, 0.95) 0.79 (0.64, 0.95) 0.7 (-1.1, 2.1) NS
Dtrab, mg
HA/cc
124.6 (110.2, 146.9) 123.9 (110.5, 148.4) 0.3 (-1.4, 2.2) NS 136.4 (89.7, 150.7) 136.4 (92.6, 150.3) 1.3 (–0.3, 2.7) 0.09
Dmeta, mg
HA/cc
181.4 (160.5, 209.3) 184.9 (154.5, 213.5) 0.3 (-1.1, 1.6) NS 193.9 (153.2, 211.4) 193.0 (157.7,215.1) 0.7 (-0.3, 1.8) 0.05
Dinn, mg
HA/cc
90.9 (69.8, 105.8) 89.6 (71.8, 108.7) 0.9 (-2.4, 3.03) NS 88.6 (48.0, 111.6) 87.3 (50.0, 113.2) 0.5 (-1.3, 4.5) NS
BV/TV 0.10 (0.09, 0.12) 0.10 (0.09,0.12) 0.3 (-1.4, 2.2) NS 0.11 (0.08, 0.13) 0.11 (0.08, 0.13) 1.3 (-0.3,2.7) 0.08
Tb.N, 1/mm 1.49 (1.33, 1.62) 1.41 (1.29, 1.57) -3.6 (-8.9, 1.7) 0.06 1.54 (1.37, 1.62) 1.52 (1.32, 1.71) -0.3 (-4.5, 3.6) NS
Tb.Th, mm 0.07 (0.07, 0.08) 0.07 (0.07, 0.09) 2.7 (-2.5, 10.3) NS 0.07 (0.06, 0.08) 0.07 (0.06, 0.09) 0.9 (-2.3, 5.2) NS
Tb.Sp, mm 0.60 (0.54, 0.68) 0.63 (0.56,0.71) 3.9 (-1.6, 9.5) 0.04 0.57 (0.55, 0.69) 0.59 (0.52, 0.68) 0.05 (-3.8, 4.8) NS
Tb.1/N.SD,
mm
0.25 (0.23, 0.28) 0.27 (0.23, 0.31) 0.65 (-2.4, 5.6) NS 0.25 (0.22, 0.30) 0.26 (0.22, 0.30) -0.15 (-1.7,
2.1)
NS
Values are median (IQR). aBMD, area bone mineral density; D100, average bone density; Dtrab, trabecular bone density; Dcomp, cortical bone density; Dinn, inner
trabecular bone density; Dmeta, meta-trabecular bone density; Ct.Th, cortical thickness; BV/TV, trabecular bone volume to tissue volume; Tb.N, trabecular number;
Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; Tb.1/N.SD, standard deviation of 1/trabecular number; NS, not significant.
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[47,49]. It is acknowledged that MCID is relevant and
important. However, based on our results, we are not
able to establish that the small differences seen in the
bone quantity and quality measures in the active group
are clinically important. Nonetheless, although small dif-
ferences were found, statistical significance was detected.
Furthermore, our study did not establish the reproduci-
bility of the HR-pQct measurements. Reported by a pre-
vious study, the reproducibility of density (total,
trabecular, and cortical) measurements ranged from
0.7% to 1.5% (by using coefficient of variation) [13]. The
reproducibility of structure parameters (trabecular num-
ber, thickness, separation, and distribution, and cortical
thickness) was slightly lower, with reproducibility ran-
ging from 0.9% to 4.4%.
Other considerations in our study include the lack of
information regarding the relatively weak and nonpre-
dictive relations between transiliac biopsies, the current
“gold standard”of bone strength, and HR-pQCT scans
[50], and the accuracy of HR-pQCT assessment of com-
partmental volumetric BMD (vBMD), which can be
influenced by geometry and the density of the human
radius and tibia. These factors can thus lead to overesti-
mation of trabecular vBMD and underestimation of
fracture risks [51].
The considerations raise several issues that require
further evaluations regarding the sensitivity and specifi-
city of the different assessment tools that can ultimately
be proven to be the clinical gold standard of bone
strength and fracture risk for patients.
Nonetheless, our study is the first to show treatment-
related changes in bone architecture assessed with HR-
pQCT. It is therefore the first study to suggest that oral
ibandronate is effective in preventing bone loss with this
novel technology, implying a potential for prospective
assessments in future studies in patients with SLE
receiving long-term glucocorticoid treatment.
Conclusions
In conclusion, we observed improvement of aBMD and
preservation of microarchitecture in patients with SLE
receiving long-term prednisolone who were treated with
oral ibandronate. Future studies using HR-pQCT in a
l a r g es a m p l eo fp a t i e n t sa nd for a longer treatment
duration, as well as comparative data on normal healthy
subjects, are needed.
Abbreviations
μCT: microcomputed tomography; BMI: body mass index; BV/TV: trabecular
bone volume per tissue volume; Ct.Th: cortical thickness; D100: average
bone density; Dcomp: cortical bone density; Dinn: inner trabecular bone
density; Dtrab: trabecular bone density; DXA: dual-energy x-ray
absorptiometry; HR-pQCT: high-resolution pQCT; SLEDAI: Systemic Lupus
Erythematosus Disease Activity Index; SLICC: Systemic Lupus International
Collaborating Clinics/American College of Rheumatology Damage Index;
Tb.1/N.SD: standard deviation of 1/trabecular number; Tb.N: trabecular
number; Tb.Sp: trabecular separation; Tb.Th: trabecular thickness.
Acknowledgements
We thank Roche, Hong Kong Limited, for providing the study drug. Roche
had no role in the study design, data collection, data analysis, data
interpretation, or writing of the report.
Author details
1Department of Medicine, The Chinese University of Hong Kong, Prince
Wales Hospital, 30-32 Ngan Shing Street, Sha Tin, NT, Hong Kong, PR China.
2Department of Orthopedics and Traumatology, The Chinese University of
Hong Kong, Prince of Wales Hospital, 30-32 Ngan Shing Street, Sha Tin, NT,
Hong Kong, PR China.
3Jockey Club Centre of Osteoporosis Care and
Control, The Chinese University of Hong Kong, 3/F, School of Public Health,
Prince of Wales Hospital, Sha Tin, NT, Hong Kong, PR China.
4School of
Pharmacy, The Chinese University of Hong Kong, Room 626, Li Choh-ming
Basic Medical Sciences Building, Sha Tin, NT, Hong Kong, PR China.
5Department of Diagnostic Radiology and Organ Imaging, The Chinese
University of Hong Kong, Prince of Wales Hospital, 30-32 Ngan Shing Street,
Sha Tin, NT, Hong Kong, PR China.
Authors’ contributions
EKL, TYZ, and LST initiated the study and contributed to design, statistical
analysis, and drafting and revising the manuscript; VYH interpreted the data
on HRCT; JFG interpreted findings on radiographs for vertebral fractures;
VWL, KKL, AWK, ML, and KCW contributed to data processing, including data
analysis; and PCL and LQ took substantial part in the intellectual conception
and the design of the study. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 1 April 2010 Revised: 10 September 2010
Accepted: 22 October 2010 Published: 22 October 2010
References
1. Gordon C: Long-term complications of systemic lupus erythematosus.
Rheumatology (Oxford) 2002, 41:1095-1100.
2. Kipen Y, Buchbinder R, Forbes A, Strauss B, Littlejohn G, Morand E:
Prevalence of reduced bone mineral density in systemic lupus
erythematosus and the role of steroids. J Rheumatol 1997, 24:1922-1929.
3. Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop D, Rairie JE, Fitzgerald S,
Manzi S: Frequency of fractures in women with systemic lupus
erythematosus: comparison with United States population data. Arthritis
Rheum 1999, 42:882-890.
4. Zonana-Nacach A, Barr SG, Magder LS, Petri M: Damage in systemic lupus
erythematosus and its association with corticosteroids. Arthritis Rheum
2000, 43:1801-1808.
5. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J:
Health-related quality of life in postmenopausal women with low BMD
with or without prevalent vertebral fractures. J Bone Miner Res 2000,
15:1384-1392.
6. Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O, European
Vertebral Osteoporosis Study: Prevalent vertebral deformities predict
increased mortality and increased fracture rate in both men and
women: a 10-year population-based study of 598 individuals from the
Swedish cohort in the European Vertebral Osteoporosis Study.
Osteoporos Int 2003, 14:61-68.
7. van Staa TP, Leufkens HG, Cooper C: The epidemiology of corticosteroid-
induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13:777-787.
8. van Staa TP: The pathogenesis, epidemiology and management of
glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006, 79:129-137.
9. Borba VZ, Matos PG, da Silva Viana PR, Fernandes A, Sato EI, Lazaretti-
Castro M: High prevalence of vertebral deformity in premenopausal
systemic lupus erythematosus patients. Lupus 2005, 14:529-533.
10. Bultink IE, Lems WF, Kostense PJ, Dijkmans BA, Voskuyl AE: Prevalence of
and risk factors for low bone mineral density and vertebral fractures in
Li et al. Arthritis Research & Therapy 2010, 12:R198
http://arthritis-research.com/content/12/5/R198
Page 6 of 8patients with systemic lupus erythematosus. Arthritis Rheum 2005,
52:2044-2050.
11. Li EK, Tam LS, Griffith JF, Zhu TY, Li TK, Li M, Wong KC, Chan M, Lam CW,
Chu FS, Wong KK, Leung PC, Kwok A: High prevalence of asymptomatic
vertebral fractures in Chinese women with systemic lupus
erythematosus. J Rheumatol 2009, 36:1646-1652.
12. Li EK, Zhu TY, Tam LS, Hung VW, Griffith JF, Li TK, Li M, Wong KC,
Leung PC, Kwok AW, Qin L: Bone microarchitecture assessment by high-
resolution peripheral quantitative computed tomography in patients
with systemic lupus erythematosus on corticosteroids. J Rheumatol 2010,
37:1473-1479.
13. Boutroy S, Bouxsein ML, Munoz F, Delmas PD: In vivo assessment of
trabecular bone microarchitecture by high-resolution peripheral
quantitative computed tomography. J Clin Endocrinol Metab 2005,
90:6508-6515.
14. Sornay-Rendu E, Boutroy S, Munoz F, Delmas PD: Alterations of cortical
and trabecular architecture are associated with fractures in
postmenopausal women, partially independent of decreased BMD
measured by DXA: the OFELY study. J Bone Miner Res 2007, 22:425-433.
15. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S,
Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG:
Alendronate for the prevention and treatment of glucocorticoid-induced
osteoporosis: Glucocorticoid-induced Osteoporosis Intervention Study
Group. N Engl J Med 1998, 339:292-299.
16. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL,
Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA: Intermittent
etidronate therapy to prevent corticosteroid-induced osteoporosis. N
Engl J Med 1997, 337:382-387.
17. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S,
Eusebio RA, Devogelaer JP: Efficacy and safety of daily risedronate in the
treatment of corticosteroid-induced osteoporosis in men and women: a
randomized trial: European Corticosteroid-induced Osteoporosis
Treatment Study. J Bone Miner Res 2000, 15:1006-1013.
18. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-
Induced Osteoporosis: Recommendations for the prevention and
treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis
Rheum 2001, 44:1496-1503.
19. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM,
Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA: Risedronate
therapy prevents corticosteroid-induced bone loss: a twelve-month,
multicenter, randomized, double-blind, placebo-controlled, parallel-
group study. Arthritis Rheum 1999, 42:2309-2318.
20. Adachi JD: Corticosteroid-induced osteoporosis. Int J Fertil Womens Med
2001, 46:190-205.
21. Gonnelli S, Rottoli P, Cepollaro C, Pondrelli C, Cappiello V, Vagliasindi M,
Gennari C: Prevention of corticosteroid-induced osteoporosis with
alendronate in sarcoid patients. Calcif Tissue Int 1997, 61:382-385.
22. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E,
Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ,
Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH,
Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO,
Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M,
Carofano W, et al: Two-year effects of alendronate on bone mineral
density and vertebral fracture in patients receiving glucocorticoids: a
randomized, double-blind, placebo-controlled extension trial. Arthritis
Rheum 2001, 44:202-211.
23. Cooper C, Emkey RD, McDonald RH, Hawker G, Bianchi G, Wilson K,
Schimmer RC: Efficacy and safety of oral weekly ibandronate in the
treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003,
88:4609-4615.
24. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F: Intermittent intravenous
ibandronate injections reduce vertebral fracture risk in corticosteroid-
induced osteoporosis: results from a long-term comparative study.
Osteoporosis Int 2003, 14:801-807.
25. Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN: Prevalence and
treatment of decreased bone density in renal transplant recipients: a
randomized prospective trial of calcitriol versus alendronate.
Transplantation 2003, 76:1498-1502.
26. Cohen A, Sambrook P, Shane E: Management of bone loss after organ
transplantation. J Bone Miner Res 2004, 19:1919-1932.
27. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY,
Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN,
HORIZON investigators: Zoledronic acid and risedronate in the prevention
and treatment of glucocorticoid-induced osteoporosis (HORIZON): a
multicentre, double-blind, double-dummy, randomised controlled trial.
Lancet 2009, 373:1253-1263.
28. McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE,
Burdeska A, Mills T, Oral Ibandronate Study Group: Oral daily ibandronate
prevents bone loss in early postmenopausal women without
osteoporosis. J Bone Miner Res 2004, 19:11-18.
29. McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD: Efficacy and
safety of monthly oral ibandronate in the prevention of
postmenopausal bone loss. Bone 2009, 44:418-422.
30. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B,
Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD,
Kendler DL, Bolognese MA, Mairon N, Cooper C: Monthly oral ibandronate
therapy in postmenopausal osteoporosis: 1-year results from the
MOBILE study. J Bone Miner Res 2005, 20:1315-1322.
31. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL,
Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R,
Felsenberg D, Cooper C, Delmas PD, Miller PD: Efficacy and tolerability of
once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year
results from the MOBILE study. Ann Rheum Dis 2006, 65:654-661.
32. Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST,
Wasnich RD, Watts NB, Schimmer RC, Recker RR: Ibandronate produces
significant, similar antifracture efficacy in North American and European
women: new clinical findings from BONE. Curr Med Res Opin 2005,
21:391-401.
33. Rogers MJ: New insights into the molecular mechanisms of action of
bisphosphonates. Curr Pharm Des 2003, 9:2643-2658.
34. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F: The
American College of Rheumatology 1991 revised criteria for the
classification of global functional status in rheumatoid arthritis. Arthritis
Rheum 1992, 35:498-502.
35. Lynn HS, Lau EM, Au B, Leung PC: Bone mineral density reference norms
for Hong Kong Chinese. Osteoporos Int 2005, 16:1663-1668.
36. Hildebrand T, Laib A, Müller R, Dequeker J, Rüegsegger P: Direct three-
dimensional morphometric analysis of human cancellous bone:
microstructural data from spine, femur, iliac crest, and calcaneus. J Bone
Miner Res 1999, 14:1167-1174.
37. Ringe JD, Cöster A, Meng T, Schacht E, Umbach R: Treatment of
glucocorticoid-induced osteoporosis with Alfacalcidol/calcium versus
vitamin D/calcium. Calcif Tissue Int 1999, 65:337-340.
38. Reginster JY, de Froidmont C, Lecart MP, Sarlet N, Defraigne JO:
Alphacalcidol in prevention of glucocorticoid-induced osteoporosis.
Calcif Tissue Int 1999, 65:328-331.
39. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC: Inhibition of
osteoblastogenesis and promotion of apoptosis of osteoblasts and
osteocytes by glucocorticoids. J Clin Invest 1998, 102:274-282.
40. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR,
Meunier PJ: Comparison of trabecular bone microarchitecture and
remodeling in glucocorticoid-induced and postmenopausal
osteoporosis. J Bone Mienr Res 2001, 16:97-103.
41. Akahoshi S, Sakai A, Arita S, Ikeda S, Morishita Y, Tsutsumi H, Ito M,
Shiraishi A, Nakamura T: Modulation of bone turnover by Alfacalcidol
and/or alendronate does not prevent glucocorticoid-induced
osteoporosis in growing minipigs. J Bone Miner Metab 2005, 23:341-350.
42. Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, Kinney JH,
Bonewald LF: Glucocorticoid-treated mice have localized changes in
trabecular bone material properties and osteocyte lacunar size that are
not observed in placebo-treated or estrogen-deficient mice. J Bone Miner
Res 2006, 21:466-476.
43. Bhattoa HP, Bettembuk P, Balogh A, Szegedi G, Kiss E: Bone mineral
density in women with systemic lupus erythematosus. Clin Rheumatol
2002, 21:135-141.
44. Chavassieux PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates AJ,
Hamdy NA, Malice MP, Freedholm D, Meunier PJ: Effects of alendronate
on bone quality and remodeling in glucocorticoid-induced osteoporosis:
a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000,
15:754-762.
Li et al. Arthritis Research & Therapy 2010, 12:R198
http://arthritis-research.com/content/12/5/R198
Page 7 of 845. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD:
Risedronate preserves bone architecture in postmenopausal women
with osteoporosis as measured by three-dimensional microcomputed
tomography. Bone 2004, 34:736-746.
46. Nuzzo S, Lafage-Proust MH, Martin-Badosa E, Boivin G, Thomas T,
Alexandre C, Peyrin F: Synchrotron radiation microtomography allows the
analysis of three-dimensional microarchitecture and degree of
mineralization of human iliac crest biopsy specimens: effects of
etidronate treatment. J Bone Miner Res 2002, 17:1372-1382.
47. Recker RR, Ste-Marie LG, Langdahl B, Masanauskaite D, Ethgen D,
Delmas PD: Oral ibandronate preserves trabecular microarchitecture:
micro-computed tomography findings from the oral ibandronate
osteoporosis vertebral fracture trial in North America and Europe study.
J Clin Densitom 2009, 12:71-76.
48. Greenspan SL, Perera S, Recker R, Wagner JM, Greeley P, Gomberg BR,
Seaman P, Kleerekoper M: Changes in trabecular microarchitecture in
postmenopausal women on bisphonate therapy. Bone 2010,
46:1006-1010.
49. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA,
Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F,
Gasser J, Eriksen EF: Effects of intravenous zoledronic acid once yearly on
bone remodeling and bone structure. J Bone Miner Res 2008, 23:6-16.
50. Cohen A, Dempster DW, Müller R, Guo XE, Nickolas TL, Liu XS, Zhang XH,
Wirth AJ, van Lenthe GH, Kohler T, McMahon DJ, Zhou H, Rubin MR,
Bilezikian JP, Lappe JM, Recker RR, Shane E: Assessment of trabecular and
cortical architecture and mechanical competence of bone by high-
resolution peripheral computed tomography: comparison with transiliac
bone biopsy. Osteoporos Int 2010, 21:263-273.
51. Sekhon K, Kazakia GJ, Burghardt AJ, Hermannsson B, Majumdar S: Accuracy
of volumetric bone mineral density measurement in high-resolution
peripheral quantitative computed tomography. Bone 2009, 45:473-479.
doi:10.1186/ar3170
Cite this article as: Li et al.: Ibandronate increases cortical bone density
in patients with systemic lupus erythematosus on long-term
glucocorticoid. Arthritis Research & Therapy 2010 12:R198.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Li et al. Arthritis Research & Therapy 2010, 12:R198
http://arthritis-research.com/content/12/5/R198
Page 8 of 8